CORE--CLINICAL

临床核心（CC）将提供招募、表征和入组的结构， 参与CCNMD的患者提出了研究方案，特别是Abi-Dargham和Laruelle的项目，同时保持最高的安全和道德标准。核心小组的任务将包括： 1)招聘招募将是集中的，将针对广泛的患者， 精神分裂症，包括首次发作患者;急性加重期慢性患者;稳定门诊患者;国家机构中的慢性住院患者。对照组将从纽约州立精神病研究所（NYSPI）的正常对照组招募。 2)诊断/评估。我们将严格诊断参加CCNMD的患者 研究方案，并在精神病理学的多个领域（例如，特质相关症状，病程和神经认知变量）中表征他们的状况。我们将通过集中培训评分员来确保评估人员和措施的一致性，以实现和保持评分员之间的可靠性。 3)我们将监督患者在不同协议之间的流动，同时在NYSPt（SRU）的精神分裂症研究单位，以及他们在精神分裂症研究诊所（SRC）的治疗和随访。 我们还将收集血液样本进行基因研究，这些研究将集中在康拉德·吉利安的基因组中心。 4)Eillics和安全委员会：该委员会将审查所有研究的伦理方面。特别是，与弱势群体的药物流失和能力评估有关的问题将是该委员会关注的中心，以确保研究受试者的保护和安全。

The Clinical Core (CC) will provide a structure for recruitment, characterization and enrollment of patients involved in the CCNMD proposed research protocols, in particular projects by Abi-Dargham and Laruelle, while maintaining the highest standards of safety and ethics. Missions of the core will include: 1) Recruitment. Recruitment will be centralized and will target a broad range of patients with schizophrenia including first episode patients; chronic patients in acute exacerbation; stable outpatients; chronic inpatient s in state facilities. Controls wilt be recruited from the Normal Controls Unit at the New York State Psychiatric Institute (NYSPI). 2) Diagnosis / Assessment. We will rigorously diagnose patients participating in the CCNMD' s research protocols and characterize their conditions across multiple domains of psychopathology (e.g. trait-related symptom, course of illness, and neurocognitive variables). We will ensure uniformity of assessmenfs and measures over timei by centralizing the training of raters to achieve and maintain interrater reiiability. 3) We will oversee the flow of patients between the dlfferent protocols while oni the Schizophrenia Research Unit at NYSPt (SRU), and their treatment and follow up in the Schizophrenia Research Clinic (SRC). We will also colllect blood samples for genetic studies which will be centralized in Conrad Giiiiam's Genome Center. 4) Committee for Eillics and Safety: This committee will review the ethical aspects of all studies. In particular, issues relating to medication washouts and capacity evaluations in vulnerable populations will be at the center of this committee's concerns, to ensure protection and safety of research subjects.